News & Articles

Our Network

Long-term ALPHA Phase III trial data showed danicopan as add-on to Ultomiris or Soliris sustained clinical improvements in subset of patients with PNH experiencing clinically significant extravascular haemolysis

Tags:

#Research #Clinical research #PHN #AstraZeneca #Rare disease
Long-term ALPHA Phase III trial data showed danicopan as add-on to Ultomiris or Soliris sustained clinical improvements in subset of patients with PNH experiencing clinically significant extravascular haemolysis

Data demonstrated effective control of intravascular and extravascular haemolysis through 48 weeks. Results showed increase in mean haemoglobin levels were maintained through 48 weeks.